Brief: Gensight Biologics End-December Cash And Cash Equivalents At 44.3 Million Euros

Gensight Biologics SA

18/01/2022 06:35

Jan 18 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * REPORTS CASH POSITION AS OF DECEMBER 31, 2021, AND
PROVIDES
OPERATIONAL UPDATE
    * GENSIGHT BIOLOGICS' CASH AND CASH EQUIVALENTS TOTALED EUR
44.3
MILLION AS OF DECEMBER 31, 2021, COMPARED TO EUR 49.1 MILLION AS
OF SEPTEMBER 30, 2021.
    * WITH A CURRENT RUNWAY TO Q1 2023, WE ARE FOCUSING OUR
RESOURCES
IN 2022 ON STRENGTHENING COMMERCIAL ORGANIZATION FOR LUMEVOQ
WHILE ADVANCING GS030 AS A PIONEERING OPTOGENETICS TREATMENT
    * WE WILL CONTINUE TO BE OPPORTUNISTIC AND SEEK OPTIMAL
CONDITIONS
TO FINANCE COMMERCIAL LAUNCH OF LUMEVOQ EARLY 2023

Source text for Eikon:  ID:nBw2yfT4ya 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))